Gene therapy has become a clinical reality.
Adeno-associated virus (AAV) vectors are safe and efficient gene transfer tools based on naturally occurring non-pathogenic AAVs. AAV-based vectors have been extensively evaluated in preclinical and clinical studies and are increasingly used in the treatment of previously incurable diseases. These vectors have proven to be safe and efficient for the long-term expression of supplemented transgenes. Nevertheless, a broader use of AAVs in gene therapy is currently hampered by two important factors:
1) The limited DNA uptake capacity, which precludes the treatment of large genes
2) The limited ability to cross biological barriers, which demands local delivery and restricts the route of administration.
At ViGeneron we have developed two next-generation gene therapy platforms designed to overcome the above-mentioned limitations of existing AAV-based gene therapies.
ViGeneron’s pipeline is built on our novel and proprietary AAV technology platforms and addresses ophthalmic diseases with high unmet medical need.
Novel AAV Technology Platforms
vgAAV vector platform
vgAAV, ViGeneron’s proprietary AAV Vector platform, is our next generation vector platform based on novel engineered AAV capsids
In a unique in vivo directed-evolution approach we generated our vgAAV vectors. The vgAAV vector platform enables a superior transduction of target cells and is designed to efficiently cross biological barriers. These attributes allow vgAAV vectors to target a broad spectrum of cell types in the retina, thus enabling intravitreal, less invasive treatment administration. vgAAV’s capability to cross biological barriers makes vgAAVs also attractive tools for applications beyond ophthalmology.
vgAAV, the novel and proprietary technology platform.
- Unique: vgAAVs are uniquely engineered AAV capsids with novel properties
- Proprietary: the vgAAV technology is fully owned by ViGeneron
- Efficient: vgAAVs efficiently transduce target cells
- Enabling: vgAAVs overcome biological barriers and enable novel, less invasive routes of administration
- Easy to produce: vgAAVs are easily produced in high yields
- Broadly applicable: vgAAVs are used for ophthalmology programs and have the potential to be applied to other tissues, such as the central nervous system.
REVeRT vector platform
REVeRT, Reconstitution via mRNA trans-splicing, is our next generation vector platform for transfer of large genes
Messenger RNA (mRNA) splicing is a very efficient cellular process for the seamless ligation of adjacent protein coding sequences, thereby enabling the formation of a functional gene product. The splicing process, which normally takes place on a single pre-mRNA molecule (cis-splicing), can also be used to ligate two separate mRNA molecules. The latter is referred to as mRNA trans-splicing and is the basis of ViGeneron’s REVeRT technology.
REVeRT was developed to overcome the limited genome capacity of AAVs (<5Kb).
This technology offers a breakthrough in gene size limitations using dual AAV vector approaches. REVeRT enables highly efficient and precise reconstitution of two mRNAs encoding the proximal and distal portions of a large protein of interest. The split gene parts are packaged into individual vgAAV vectors, mixed, and co-delivered to the target tissue. REVeRT achieves high reconstitution efficiency at mRNA and protein levels.
REVeRT is a novel tool for the efficient delivery of large genes
- Unique: REVeRT is the dual AAV vector technology working at the mRNA level
- Proprietary: REVeRT technology is fully owned by ViGeneron
- Efficient: REVeRT utilizes the highly efficient cellular splicing machinery
- Specific: REVeRT generates the desired full-length protein with high precision
- Seamless: REVeRT results in seamless ligation of sequences
- Broadly applicable: REVeRT can be used for any disease indication
An overview of the most important papers about our innovative solutions published by our team.
1. Koch S, Sothilingam V, Garcia Garrido M, Tanimoto N, Becirovic E, Koch F, Seide C, Beck S, Seeliger M, Biel M, Mühlfriedel R, Michalakis S. Gene therapy restores vision and delays degeneration in the CNGB1(-/-) mouse model of retinitis pigmentosa. Hum Mol Genet. 2012;21(20):4486-96 – more
2. Riedmayr LM, Böhm S, Biel M, Becirovic E. Enigmatic rhodopsin mutation creates an exceptionally strong splice acceptor site. Hum Mol Genet. 2019;29:295-304. doi: 10.1093/hmg/ddz291 – more
3. Fischer MD, Michalakis S, Wilhelm B, Zobor D, Muehlfriedel R, Kohl S, Weisschuh N, Ochakovski GA, Klein R, Schoen C, Sothilingam V, Garcia-Garrido M, Kuehlewein L, Kahle N, Werner A, Dauletbekov D, Paquet-Durand F, Tsang S, Martus P, Peters T, Seeliger M, Bartz-Schmidt KU, Ueffing M, Zrenner E, Biel M, Wissinger B. Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia: A Nonrandomized Controlled Trial. JAMA Ophthalmol. 2020;doi: 10.1001/jamaophthalmol.2020.1032. [Epub ahead of print] – more
4. Böhm S, Splith V, Riedmayr LM, Rötzer RD, Gasparoni G, Nordsröm KJV, Wagner J, Hinrichsmeyer KS, Walter J, Wahl-Schott C, Fenske S, Biel M, Michalakis S, Becirovic E. A gene therapy for inherited blindness using dCas9-VPR-mediated transcripional activation. Science Advances 2020;vol. 6, no. 34, eaba5614 doi: 10.1126/sciadv.aba5614 – more
5. Panagiotopoulos AL, Karguth N, Pavlou M, Böhm S, Gasparoni G, Walter J, Graf A, Blum H, Biel M, Riedmayr LM, Becirovic E. Antisense Oligonucleotide- and CRISPR-Cas9-Mediated Rescue of mRNA Splicing for a Deep Intronic CLRN1 Mutation. Mol Ther Nucleic Acids 2020;21:1050-106 – more